Successful Treatment of Refractory Hailey-Hailey Disease with Narrow-Band Ultraviolet B Light: A Case Series

To evaluate the efficacy and safety of narrow-band ultraviolet B (NB-UVB) in treating refractory Hailey-Hailey Disease (HHD), four HHD patients (36-68 years old, disease duration 5-20 years) were included. NB-UVB was administered twice weekly, with initial doses 0.300-0.500 J/cm2; and 0.050 J/cm2; increments per session, and some patients received concurrent topical medications; follow-up lasted 1.5-3 months, with outcomes assessed via lesion body surface area (BSA) and Visual Analog Scale scores (disease severity, Refractory Visual Analog Scale, pruritus). Onset time was 0.25-4 months: 2 patients achieved complete lesion clearance, the other 2 had 60% and 87.5% BSA reduction, and the longest remission was 18 months; only 1 patient reported moderate irradiation-site pain, with no severe adverse events. NB-UVB shows satisfactory efficacy and good safety in refractory HHD and may serve as a viable treatment option.